OPLAH Antibody

What is OPLAH and why is it important in biomedical research?

OPLAH (5-Oxoprolinase ATP-Hydrolysing) is an enzyme involved in glutathione metabolism that catalyzes the conversion of 5-oxo-L-proline to L-glutamate while hydrolyzing ATP to ADP and inorganic phosphate . Its importance in research stems from its role in antioxidant pathways and detoxification mechanisms. Glutathione has well-documented antioxidant and detoxifying effects, capturing and facilitating the excretion of cell-damaging compounds . Recent studies have highlighted OPLAH's significance in cancer research, particularly as a potential biomarker for prognosis in esophageal squamous cell carcinoma (ESCC) . The enzyme appears to contribute to treatment resistance through activation of glutathione metabolism, making it a valuable target for both diagnostic and therapeutic research .

What detection methods are available for OPLAH protein studies?

OPLAH protein can be detected through several validated methodologies:

• Immunohistochemistry (IHC): Commonly used to evaluate OPLAH protein expression in tissue samples. Research has successfully employed IHC to stratify patient prognosis based on OPLAH staining intensity in cancer tissues .

• Enzyme-Linked Immunosorbent Assay (ELISA): Particularly useful for quantifying OPLAH protein in serum samples. Commercial ELISA kits are available that allow researchers to measure OPLAH concentration in ng/ml .

• Western Blotting (WB): Effective for detecting and semi-quantifying OPLAH protein expression in cell or tissue lysates .

When selecting antibodies for these applications, researchers should consider polyclonal antibodies that have been validated for their specific experimental system (human, mouse, or rat samples) .

How should OPLAH antibodies be stored and handled to maintain optimal activity?

OPLAH antibodies require specific storage and handling conditions to preserve their activity:

• Storage temperature: Store at -20°C or -80°C upon receipt .

• Formulation stability: Most commercial OPLAH antibodies are supplied in a liquid format with PBS containing 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Avoid freeze/thaw cycles: Repeated freezing and thawing significantly diminishes antibody performance .

• Safety precautions: Note that sodium azide is a hazardous preservative in many antibody preparations and should be handled only by trained personnel .

• Working dilution determination: Optimal working dilutions should be determined experimentally for each specific application and may vary between Western blotting, IHC, and ELISA protocols .

How can OPLAH expression data be integrated with clinical parameters for biomarker validation?

Integration of OPLAH expression data with clinical parameters requires a multi-dimensional approach:

• Comprehensive transcriptome analysis: Begin with RNA-seq or microarray data to identify OPLAH as a differentially expressed gene between tumor and normal tissues, as demonstrated in ESCC research using The Cancer Genome Atlas (TCGA) data .

• Protein validation strategy: Confirm transcriptomic findings through protein-level analysis using techniques such as:

  • Tissue microarrays with IHC (n=177 in the ESCC study)

  • Serum protein quantification via ELISA (n=54 in the ESCC study)

• Statistical methodology: Apply appropriate statistical tests for different data types:

  • Continuous variables: Student's t-test

  • Categorical variables: χ² tests or Fisher's exact tests

  • Survival analysis: Kaplan-Meier method with log-rank tests

  • Multivariable analysis: Cox proportional hazard model

• Clinical correlation analysis: Examine associations between OPLAH expression and established clinical parameters such as tumor depth, lymph node metastasis status, and clinical stage .

The robustness of OPLAH as a biomarker should be verified through multiple independent cohorts, as exemplified in the ESCC study which utilized both public databases and institutional patient cohorts .

What are the methodological considerations when using OPLAH antibodies for comparative studies between different tissue types?

When designing comparative studies using OPLAH antibodies across different tissue types, researchers should consider:

• Antibody selection parameters:

  • Confirmed cross-reactivity with target species (human, mouse, rat)

  • Validated applications (WB, IHC, ELISA)

  • Epitope location (N-terminal vs C-terminal) may affect detection in different contexts

• Standardization protocols:

  • Use identical fixation and processing methods across all tissue types

  • Include positive and negative controls in each experimental batch

  • Employ automated staining platforms when possible to reduce technical variability

• Quantification methods:

  • For IHC: Implement standardized scoring systems (e.g., H-score, Allred score)

  • For WB: Use appropriate housekeeping proteins specific to each tissue type

  • For ELISA: Develop tissue-specific standard curves

• Technical validation:

  • Confirm specificity through peptide competition assays

  • Validate results using multiple antibodies targeting different epitopes

  • Consider complementary RNA-level analysis (qPCR, RNA-seq) to corroborate protein findings

• Statistical considerations:

  • Account for tissue-specific baseline expression levels

  • Apply appropriate normalization methods

  • Consider batch effects in multi-tissue analyses

How does OPLAH protein expression correlate with glutathione metabolism in cancer progression models?

The relationship between OPLAH expression and glutathione metabolism in cancer progression is complex and multifaceted:

• Mechanistic framework:

  • OPLAH catalyzes the conversion of 5-oxo-L-proline to L-glutamate, a critical step in the γ-glutamyl cycle of glutathione metabolism

  • Glutathione serves dual functions in cancer cells:

    • Protects against oxidative damage

    • Facilitates detoxification of xenobiotics, including chemotherapeutic agents

• Treatment resistance mechanisms:

  • High glutathione concentrations in cancer cells contribute to resistance against:

    • Platinum-based chemotherapies (e.g., CDDP)

    • Radiation therapy

  • OPLAH overexpression may enhance this protective mechanism by supporting glutathione recycling

• Experimental evidence:

  • In ESCC studies, OPLAH mRNA overexpression correlated with poorer patient prognosis

  • Serum OPLAH protein concentration decreased following neoadjuvant chemotherapy, suggesting responsiveness to treatment

  • OPLAH expression was independent of other clinicopathological factors, indicating potential as a novel independent prognostic factor

• Research implications:

  • Inhibition of glutathione metabolism enzymes may restore sensitivity to chemotherapeutic agents

  • OPLAH targeting could potentially overcome treatment resistance in certain cancer types

  • Combined assessment of multiple glutathione pathway enzymes may provide more comprehensive prognostic information

What are the optimal protocols for detecting OPLAH in tissue microarrays versus whole tissue sections?

Optimal protocols for OPLAH detection differ between tissue microarrays (TMAs) and whole tissue sections:

Table 1: Comparison of OPLAH Detection Protocols for Different Tissue Preparations

For both formats, researchers should:

• Optimize antibody concentration through titration experiments

• Validate staining pattern through comparison with transcript data (RNA-seq or qPCR)

• Employ digital pathology and image analysis software for more objective quantification

• Consider multiplexed immunofluorescence to assess OPLAH in relation to other glutathione pathway components

Research has demonstrated that OPLAH protein levels assessed by IHC successfully stratified ESCC patient prognosis, confirming the validity of these protocols when properly optimized .

How can researchers investigate potential post-translational modifications of OPLAH and their functional significance?

Investigating post-translational modifications (PTMs) of OPLAH requires sophisticated methodological approaches:

• Identification of potential PTMs:

  • Phosphorylation: Use phospho-specific antibodies in Western blots

  • Glycosylation: Employ lectin-based affinity methods or glycosidase treatments

  • Ubiquitination: Conduct immunoprecipitation with ubiquitin-specific antibodies

• Mass spectrometry approaches:

  • Perform tandem mass spectrometry (MS/MS) on immunoprecipitated OPLAH

  • Use targeted multiple reaction monitoring (MRM) to quantify specific modified peptides

  • Apply stable isotope labeling techniques to compare PTM levels between conditions

• Functional characterization:

  • Site-directed mutagenesis of predicted modification sites

  • In vitro enzyme activity assays comparing wild-type and mutant OPLAH

  • Cell-based assays examining:

    • Protein stability and half-life

    • Subcellular localization

    • Protein-protein interactions

• Biological significance assessment:

  • Evaluate PTM status in normal versus tumor tissues

  • Correlate PTM levels with enzyme activity and glutathione metabolism

  • Investigate changes in PTM profiles following treatment with chemotherapeutic agents

• Regulatory network analysis:

  • Identify kinases, phosphatases, or other enzymes responsible for OPLAH modification

  • Determine if glutathione levels feedback to regulate OPLAH PTMs

  • Map PTM patterns to specific cancer progression stages or treatment resistance phenotypes

This multi-layered approach would provide insight into how OPLAH activity is regulated beyond transcriptional control, potentially revealing new therapeutic vulnerabilities in cancer cells with aberrant glutathione metabolism .

What controls should be included when validating OPLAH antibody specificity for novel applications?

Comprehensive validation of OPLAH antibody specificity requires multiple control experiments:

• Positive controls:

  • Tissues or cell lines with confirmed high OPLAH expression (e.g., liver tissue)

  • Recombinant OPLAH protein for Western blot standardization

  • Cells transfected with OPLAH expression vectors

• Negative controls:

  • OPLAH knockout or knockdown cells/tissues (CRISPR-Cas9 or siRNA)

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls matched to the primary antibody species and class

• Peptide competition assays:

  • Pre-incubate antibody with excess immunizing peptide

  • Perform parallel experiments with competed and non-competed antibody

  • Specific signals should be eliminated by peptide competition

• Cross-reactivity assessment:

  • Test on tissues from multiple species if cross-reactivity is claimed

  • Evaluate potential cross-reaction with related enzymes in the glutathione pathway

  • Confirm epitope uniqueness through sequence alignment analysis

• Orthogonal validation:

  • Correlate protein detection with mRNA expression (qPCR or RNA-seq)

  • Compare results using multiple antibodies targeting different OPLAH epitopes

  • Confirm subcellular localization patterns with tagged OPLAH constructs

These validation steps are essential before applying OPLAH antibodies to novel research questions, particularly when investigating its potential as a biomarker in different cancer types beyond ESCC .

How should researchers account for glutathione pathway variations when analyzing OPLAH expression across different cancer types?

When analyzing OPLAH expression across cancer types, researchers must consider the broader glutathione metabolism context:

This comprehensive approach would enable meaningful comparison of OPLAH's role across cancer types while accounting for the inherent variability in glutathione metabolism between different tissues and tumor microenvironments .

What are the technical considerations when measuring both tissue and serum OPLAH levels in longitudinal patient studies?

Longitudinal monitoring of OPLAH in both tissue and serum presents unique technical challenges:

• Sample collection standardization:

  • Tissue biopsies:

    • Standardize collection methodology and tissue processing

    • Consider tumor heterogeneity through multiple sampling sites

    • Maintain consistent fixation times and protocols

  • Serum collection:

    • Standardize collection time (circadian variations)

    • Use consistent processing protocols (clotting time, centrifugation)

    • Implement strict storage conditions (-80°C, avoid freeze-thaw)

• Analytical consistency:

  • Use the same antibody lots throughout the study when possible

  • Include internal control samples in each analytical batch

  • Implement quality control procedures with defined acceptance criteria

• Correlation methodology:

  • Paired tissue-serum analysis when feasible

  • Statistical approaches for handling missing data points

  • Time-series analysis techniques for trajectory assessment

• Clinical parameter integration:

  • Record treatment interventions and response metrics

  • Document disease progression events

  • Track changes in relevant laboratory values

• Technical validation measures:

  • For IHC: Digital pathology with automated quantification

  • For ELISA: Duplicate or triplicate measurements

  • Regular calibration of all measuring instruments

Research has demonstrated that serum OPLAH protein concentrations may reflect systemic tumor burden and decrease following neoadjuvant chemotherapy, highlighting the potential value of longitudinal monitoring . Pre-neoadjuvant chemotherapy serum OPLAH protein concentrations were significantly associated with clinical tumor depth and node positivity, indicating its potential as a monitoring biomarker .

How should researchers interpret discordant results between OPLAH mRNA and protein expression levels?

Discordances between OPLAH mRNA and protein levels require systematic analysis:

• Potential biological explanations:

  • Post-transcriptional regulation (miRNAs, RNA-binding proteins)

  • Post-translational modifications affecting protein stability

  • Differential regulation of OPLAH in response to cellular stress

  • Protein secretion versus intracellular retention

• Technical considerations:

  • Sample collection timing (mRNA changes precede protein changes)

  • Different sensitivities of detection methods

  • Antibody specificity issues

  • RNA quality and degradation effects

• Analytical approach:

  • Calculate correlation coefficients between mRNA and protein levels

  • Perform time-course experiments to detect temporal relationships

  • Investigate potential regulatory mechanisms through pathway analysis

  • Consider spatial heterogeneity in tissue samples

• Resolution strategies:

  • Use multiple methodologies to confirm both mRNA and protein levels

  • Investigate post-transcriptional regulators specific to OPLAH

  • Measure protein half-life and stability in different conditions

  • Examine single-cell data to account for cellular heterogeneity

In esophageal squamous cell carcinoma research, both OPLAH mRNA and protein levels showed prognostic significance, though the correlation between them was not perfect, suggesting complex regulatory mechanisms . Researchers should consider that while mRNA provides insights into transcriptional regulation, protein levels ultimately determine functional activity and may better correlate with clinical outcomes .

What statistical approaches are most appropriate for correlating OPLAH expression with patient survival in multivariate analyses?

Optimal statistical approaches for correlating OPLAH expression with survival include:

• Univariate analysis fundamentals:

  • Kaplan-Meier method for survival curve generation

  • Log-rank tests for comparing survival distributions

  • Hazard ratio calculation with 95% confidence intervals

• Multivariate modeling techniques:

  • Cox proportional hazards regression

    • Verify proportional hazards assumption using Schoenfeld residuals

    • Include relevant clinicopathological covariates (stage, grade, age, etc.)

  • Competing risk models when appropriate

  • Time-dependent coefficient models if proportional hazards assumption is violated

• OPLAH expression categorization approaches:

  • Continuous variable analysis with appropriate transformations

  • Dichotomization using:

    • Median split

    • Optimal cutpoint determination (e.g., maximally selected rank statistics)

    • IHC scoring thresholds (e.g., H-score cutoffs)

  • Multiple category analysis (quartiles or IHC intensity grades)

• Model validation methods:

  • Internal validation through bootstrapping

  • Cross-validation approaches

  • External validation in independent cohorts

  • Concordance index (C-index) calculation

• Advanced considerations:

  • Interaction terms between OPLAH and treatment variables

  • Stratified analysis for specific patient subgroups

  • Joint models for longitudinal OPLAH measurements and survival

Research on ESCC has successfully implemented multivariable Cox proportional hazard models to demonstrate that high OPLAH protein expression is an independent prognostic factor for survival after surgery, with appropriate adjustment for confounding variables .

How can researchers distinguish between OPLAH's prognostic value and its potential as a predictive biomarker for treatment response?

Distinguishing prognostic from predictive biomarker value requires specific analytical approaches:

• Conceptual framework:

  • Prognostic biomarker: Informs about likely disease outcome regardless of treatment

  • Predictive biomarker: Identifies patients likely to benefit from specific interventions

• Study design requirements:

  • For prognostic value assessment:

    • Analysis in untreated patient cohorts or adjusting for treatment effects

    • Long-term follow-up across multiple outcome metrics

    • Multivariate analysis controlling for established prognostic factors

  • For predictive value assessment:

    • Treatment arm comparisons (ideally randomized)

    • Interaction testing between biomarker and treatment

    • Analysis of treatment-specific outcomes

• Statistical methodology:

  • Test for interaction between OPLAH expression and treatment in survival models

  • Calculate treatment benefit ratios in high versus low OPLAH expression groups

  • Develop prediction models incorporating OPLAH with treatment variables

• Experimental validation approaches:

  • In vitro drug sensitivity assays in OPLAH-manipulated cell lines

  • Patient-derived xenograft models with varying OPLAH expression

  • Longitudinal OPLAH measurement before, during, and after treatment

• Clinical application considerations:

  • Different thresholds may apply for prognostic versus predictive applications

  • Combination with other biomarkers may enhance either prognostic or predictive value

  • Context-specific validation for different cancer types and treatment modalities

What emerging technologies might enhance OPLAH detection sensitivity and specificity in clinical samples?

Several emerging technologies show promise for advancing OPLAH detection:

• Digital spatial profiling:

  • Enables simultaneous detection of OPLAH with other glutathione pathway components

  • Preserves spatial context within the tumor microenvironment

  • Allows single-cell resolution analysis of OPLAH expression patterns

• Aptamer-based detection systems:

  • Development of OPLAH-specific aptamers for highly sensitive detection

  • Potential for electrochemical or optical biosensor applications

  • May enable rapid point-of-care testing for OPLAH

• Digital ELISA platforms:

  • Single-molecule array (Simoa) technology for ultra-sensitive protein detection

  • Could enable detection of OPLAH in liquid biopsies beyond serum (e.g., saliva, urine)

  • Expanded dynamic range for more precise quantification

• Mass cytometry (CyTOF):

  • Metal-tagged antibodies for highly multiplexed single-cell analysis

  • Correlation of OPLAH with dozens of other cellular markers

  • Analysis of rare cell populations with distinct OPLAH expression

• Proximity ligation assays:

  • Detection of protein-protein interactions involving OPLAH

  • Potential to identify functionally active versus inactive OPLAH

  • Enhanced specificity through dual antibody recognition

• In vivo imaging approaches:

  • Development of radiolabeled or fluorescently tagged OPLAH-targeting molecules

  • Non-invasive monitoring of OPLAH expression in tumors

  • Potential for image-guided interventions based on OPLAH expression

These technologies could address current limitations in OPLAH detection and accelerate its translation into clinical applications beyond the research setting .

How might computational approaches integrate OPLAH expression data with broader -omics datasets to reveal novel biological insights?

Computational integration of OPLAH data with broader -omics platforms offers powerful new research opportunities:

• Multi-omics integration frameworks:

  • Correlation of OPLAH protein/mRNA with:

    • Metabolomics profiles (particularly glutathione pathway metabolites)

    • Transcriptome-wide expression patterns

    • Epigenetic modifications (methylation, histone marks)

    • Genomic alterations affecting glutathione metabolism

• Network biology approaches:

  • Protein-protein interaction network analysis centered on OPLAH

  • Gene regulatory network reconstruction

  • Pathway enrichment methods to contextualize OPLAH function

  • Identification of master regulators controlling OPLAH expression

• Machine learning applications:

  • Feature selection to identify optimal biomarker panels including OPLAH

  • Deep learning for prediction of treatment response based on OPLAH and related markers

  • Unsupervised clustering to identify patient subgroups with distinct OPLAH expression patterns

• Systems pharmacology models:

  • In silico prediction of drug responses based on OPLAH expression

  • Identification of synergistic drug combinations targeting glutathione metabolism

  • Simulation of metabolic flux through pathways involving OPLAH

• Clinical data integration:

  • Electronic health record mining to identify clinical correlates of OPLAH expression

  • Real-world evidence generation for OPLAH as a biomarker

  • Development of clinical decision support algorithms incorporating OPLAH status

Such computational approaches could reveal OPLAH's role within the broader context of cellular metabolism and identify previously unrecognized connections to other biological processes and disease mechanisms .

What are the methodological challenges in developing therapeutic strategies targeting OPLAH in cancer treatment?

Developing therapeutic strategies targeting OPLAH presents several methodological challenges:

• Target validation complexities:

  • Distinguishing between correlation and causation in OPLAH overexpression

  • Determining whether OPLAH is a driver or passenger in cancer progression

  • Identifying cancer types most dependent on OPLAH function

• Inhibitor development considerations:

  • Design of selective OPLAH inhibitors with minimal off-target effects

  • Optimization of physicochemical properties for appropriate tissue distribution

  • Development of appropriate in vitro assays for screening compound libraries

• Preclinical model selection:

  • Generation of appropriate cell line and animal models with varying OPLAH expression

  • Development of patient-derived xenografts that recapitulate OPLAH expression patterns

  • Creation of genetic models with inducible OPLAH modulation

• Combination strategy design:

  • Identification of synergistic combinations with standard chemotherapies

  • Determination of optimal sequencing (concurrent vs. sequential)

  • Management of potential toxicities from disrupting glutathione metabolism

• Biomarker development challenges:

  • Identification of patient populations most likely to benefit

  • Development of companion diagnostics for OPLAH expression or activity

  • Monitoring markers for treatment response and resistance development

• Clinical trial considerations:

  • Appropriate endpoint selection for trials targeting glutathione metabolism

  • Managing potential differences in OPLAH dependence across cancer subtypes

  • Accounting for compensatory mechanisms that may emerge during treatment

The observation that OPLAH is involved in glutathione metabolism and potentially contributes to treatment resistance provides a rationale for therapeutic targeting, but these methodological challenges must be addressed to translate these findings into clinical applications .